(Q30650711)

25 June 2017

Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study (English)

1 reference

25 June 2017

1 reference

Mertes G

1

1 reference

25 June 2017

1 June 2001

1 reference

Diabetes Research and Clinical Practice

25 June 2017

1 reference

25 June 2017

52

1 reference

25 June 2017

3

1 reference

25 June 2017

193-204

1 reference

The effects of theα-glucosidase inhibitor BAY g 5421 (Acarbose) on meal-stimulated elevations of circulating glucose, insulin, and triglyceride levels in man

25 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900221-2

7 January 2021

The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900221-2

7 January 2021

The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900221-2

7 January 2021

Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900221-2

7 January 2021

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900221-2

7 January 2021

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900221-2

7 January 2021

Are randomized controlled trials sufficient evidence to guide clinical practice in type II (non-insulin-dependent) diabetes mellitus?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900221-2

7 January 2021

Efficacy and safety of acarbose in the treatment of type 2 diabetes: data from a 2-year surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900221-2

7 January 2021

Alpha-glucosidase inhibition as an adjunct to the treatment of type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900221-2

7 January 2021

PROTECT interim results: a large multicenter study of patients with type II diabetes. Precose Resolution of Optimal Titration to Enhance Current Therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900221-2

7 January 2021

Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900221-2

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900221-2

7 January 2021

10.1016/S0168-8227(01)00221-2

Identifiers

DOI

1 reference

25 June 2017

1 reference

PubMed ID

11323089